Credit: Shutterstock
April 10, 2024 07:00 AM EDT
Financing
Deals
Bioregnum

Big come­back? The Q1 re­port on biotech is in, and there’s been some sput­ter­ing

John Carroll

Editor & Founder

Deal­For­ma’s Chris Doko­ma­ji­lar has been run­ning the num­bers again and backs up some of the things we were al­ready pret­ty sure about — while rais­ing new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times